SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Larry Liebman who wrote (131)12/18/1996 4:36:00 PM
From: scaram(o)uche   of 6136
 
Elegant work, but I don't really know how practical it is. That is, the protein is produced by muscle cells, where regulation is whatever you get given the AAV vector. I don't see Amgen begging them for a license, but maybe that's because I'm not looking in the correct places. That is, I think that the EPO results are largely an experimental model rather than central to the business plan. I focus on a system proposed by Ariad (ARIA), where the protein would be expressed in a "cell factory", and such expression could be tightly regulated by taking a pill.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News